Cabozantinib extends advanced RCC overall survival
Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.
Source: MedWire News - Category: Consumer Health News Tags: Kidney cancer Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Health | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology